A former lab director says Theranos 'valued PR and fundraising' over patients

Adam Rosendorff said he felt pressured to vouch for tests he did not have confidence in. His testimony appeared to tie Holmes more closely to the lab's failures.

Elizabeth Holmes

Elizabeth Holmes leaves the San Jose courthouse where her fraud trial is underway.

Photo: Jane Tyska/Digital First Media/The Mercury News via Getty Images

Former Theranos lab director Adam Rosendorff testified Friday that he repeatedly raised the alarm about bad blood tests to then-CEO Elizabeth Holmes, ultimately concluding that the company valued press and funding more than the patients.

"I was very enthusiastic working at Theranos in the beginning. Over time, I came to realize that the company really valued PR and fundraising above patient care, and I became very disillusioned," Rosendorff said on the witness stand inside the San Jose courtroom where Holmes' trial on fraud charges began this month.

The testimony of the Theranos lab director repeatedly tied Holmes to the problems at the Theranos lab, showing the CEO was well aware of the issues and included directly in complaints about the quality of the tests. She is facing charges of fraud and conspiracy to commit fraud against patients and investors. In order to prove its case, the U.S. government has to convince the jury to agree that Holmes had an intent to deceive and reject the defense's argument that she was a young CEO whose startup failed to live up to its promise.

During his testimony, Rosendorff said he felt pressured by upper management to vouch for tests he felt were "wrong." Holmes, accused co-conspirator Sunny Balwani, Daniel Young and Holmes' brother Christian were "pushing" him to rationalize or justify erroneous results, he testified: "Anything other than saying our test is inaccurate."

"At one point I started to refuse to talk to physicians. I believe I told one or two physicians that I didn't believe in the results," he added.

Rosendorff joined Theranos in early 2013 before Theranos tests were commercially available, and he was intrigued by the idea of running tests on a fingerprick of blood. "I thought it was going to be the next Apple," he said.

By that summer, a few months after joining, Rosendorff was already looking for a new job. Theranos had struck a deal with Walgreens to test patients' blood inside of the stores and was gearing up for a commercial launch in September 2013. But emails entered as evidence in the case showed that even nine days before the launch, none of Theranos' proprietary tests had been validated for use on patients.

Rosendorff raised the alarm specifically with Holmes, sending an email titled "Concerns about the launch" and asked her to delay it for a few weeks. He recounted that he met directly with Holmes in her office after the email, where she had taped on her window a paper countdown of the number of days left until going live.

"She was not her usual composed self. She was trembling," he said. When he raised his concerns, he said Holmes did not seem surprised to hear them, but was "nervous and upset." Despite his reservations, the launch went ahead as planned.

Rosendorff's concerns about the tests only amplified from there. During the roughly six hours of testimony, Assistant U.S. Attorney John Bostic spent much of it going over the accuracy of several Theranos tests that were run on its own devices or modified third-party machines. The tests included hCG levels, which are crucial to determine pregnancy, as well as cholesterol and potassium levels.

In each case, Rosendorff had expressed concern about tests being out of range, often failing quality control, and ultimately delivering incorrect results to the patients. One example which had come up in earlier testimony was about a pregnant patient whose results wrongly told her she was miscarrying when she in fact was still pregnant. Rosendorff told Holmes he was "freaking out" about the problems with the hCG tests, but she didn't seem alarmed, he said.

In an all-caps email in May 2014, Rosendorff made the call to ban the lab from running the hCG tests on Theranos devices and insisted they use the third-party devices from other manufacturers. It wasn't until he was shown emails during testimony that he found out that some employees had continued to use Theranos' proprietary devices against his orders.

In another case, the company returned potassium levels and sodium levels out of the typical ranges for blood tests far more often than he had seen in other labs. Eventually Theranos stopped reporting the results of any patients whose levels were outside of the expected ranges for certain tests like sodium.

In an email to Holmes, Rosendorff questioned the utility of the test for patients if abnormal results couldn't be delivered to the patient: "I am not sure of the clinical value of a sodium assay in which the only time as we can report it is when it is not critical, and the very situations that require accurate measurement and reporting of abnormal sodium results are voided."

Instead of removing the sodium test from the order menu, Theranos decided to simply report to patients that the results were voided and made it seem like a temporary thing, he said. Rosendorff felt like this was misleading doctors, because often they would specifically be testing for those things if they had come out of range.

Ultimately, Holmes' brother Christian, who handled customer complaints at the lab, also raised concerns directly to his sister in a September 2014 email. "I am always confident in our technology, but it's pretty obvious we have issues with calcium, potassium and sodium specifically," he wrote.

By that point, Rosendorff said he had entirely lost confidence in the technology and that the issue was broader than the three tests.

Eventually, Rosendorff started forwarding messages that documented concerns with a variety of tests to his personal Gmail account, in violation of the company's nondisclosure agreements.

"I wasn't confident that Theranos would preserve these emails in the event of a CMS and government investigation," Rosendorff said, referring to the agency that regulated labs like Theranos. "I wanted to protect myself."

He eventually left Theranos at the end of 2014, disillusioned by the startup that he once thought would be the next Apple. Today, Rosendorff doesn't even list Theranos on his LinkedIn by name.

Rosendorff's testimony is expected to continue in the Theranos trial on Tuesday. Follow Protocol's coverage of the Theranos trial here.

Podcasts

Should startups be scared?

Stock market turmoil is making VCs skittish. Could now be the best time to start a company?

yellow sticky notes on gray wall
Photo by Startaê Team on Unsplash

This week, we break down why Elon Musk is tweeting about the S&P 500's ESG rankings — and why he might be right to be mad. Then we discuss how tech companies are failing to prevent mass shootings, and why the new Texas social media law might make it more difficult for platforms to be proactive.

Then Protocol's Biz Carson, author of the weekly VC newsletter Pipeline, joins us to explain the state of venture capital amidst plunging stocks and declining revenues. Should founders start panicking? The answer might surprise you.

Keep Reading Show less
Caitlin McGarry

Caitlin McGarry is the news editor at Protocol.

Sponsored Content

Why the digital transformation of industries is creating a more sustainable future

Qualcomm’s chief sustainability officer Angela Baker on how companies can view going “digital” as a way not only toward growth, as laid out in a recent report, but also toward establishing and meeting environmental, social and governance goals.

Three letters dominate business practice at present: ESG, or environmental, social and governance goals. The number of mentions of the environment in financial earnings has doubled in the last five years, according to GlobalData: 600,000 companies mentioned the term in their annual or quarterly results last year.

But meeting those ESG goals can be a challenge — one that businesses can’t and shouldn’t take lightly. Ahead of an exclusive fireside chat at Davos, Angela Baker, chief sustainability officer at Qualcomm, sat down with Protocol to speak about how best to achieve those targets and how Qualcomm thinks about its own sustainability strategy, net zero commitment, other ESG targets and more.

Keep Reading Show less
Chris Stokel-Walker

Chris Stokel-Walker is a freelance technology and culture journalist and author of "YouTubers: How YouTube Shook Up TV and Created a New Generation of Stars." His work has been published in The New York Times, The Guardian and Wired.

Fintech

Data privacy and harassment could spoil Grindr’s Wall Street romance

As it pursues a long-held goal of going public, the gay dating app has to confront its demons.

Grindr may finally be a public company.

Illustration: woocat/iStock/Getty Images Plus; Protocol

Grindr's looking for more than just a hookup with Wall Street. Finding a stable relationship may be tough.

The location-based dating app favored by gay men was a pioneer, predating Tinder by three years. It’s bounced from owner to owner after founder Joel Simkhai sold it in 2018 for $245 million. A SPAC merger could be the answer, but businesses serving the LGBTQ+ community have had trouble courting investors. And Grindr has its own unique set of challenges.

Keep Reading Show less
Veronica Irwin

Veronica Irwin (@vronirwin) is a San Francisco-based reporter at Protocol, covering breaking news. Previously she was at the San Francisco Examiner, covering tech from a hyper-local angle. Before that, her byline was featured in SF Weekly, The Nation, Techworker, Ms. Magazine and The Frisc.

Inside the Crypto Cannabis Club

As crypto crashes, an NFT weed club holds on to the high.

The Crypto Cannabis Club’s Discord has 23,000 subscribers, with 28 chapters globally.

Photo: Nat Rubio-Licht/Protocol

On a Saturday night in downtown Los Angeles, a group of high strangers gathered in a smoky, colorful venue less than a mile from Crypto.com Arena. The vibe was relaxed but excited, and the partygoers, many of whom were meeting each other for the very first time, greeted each other like old friends, calling each other by their Discord names. The mood was celebratory: The Crypto Cannabis Club, an NFT community for stoners, was gathering to celebrate the launch of its metaverse dispensary.

The warmth and belonging of the weed-filled party was a contrast to the metaverse store, which was underwhelming by comparison. But the dispensary launch and the NFTs required to buy into the group are just an excuse: As with most Web3 projects, it’s really about the community. Even though crypto is crashing, taking NFTs with it, the Crypto Cannabis Club is unphased, CEO Ryan Hunter told Protocol.

Keep Reading Show less
Nat Rubio-Licht

Nat Rubio-Licht is a Los Angeles-based news writer at Protocol. They graduated from Syracuse University with a degree in newspaper and online journalism in May 2020. Prior to joining the team, they worked at the Los Angeles Business Journal as a technology and aerospace reporter.

Climate

The minerals we need to save the planet are getting way too expensive

Supply chain problems and rising demand have sent prices spiraling upward for the minerals and metals essential for the clean energy transition.

Critical mineral prices have exploded over the past year.

Photo: Andrey Rudakov/Bloomberg via Getty Images

The newest source of the alarm bells echoing throughout the renewables industry? Spiking critical mineral and metal prices.

According to a new report from the International Energy Agency, a maelstrom of rising demand and tattered supply chains have caused prices for the materials needed for clean energy technologies to soar in the last year. And this increase has only accelerated since 2022 began.

Keep Reading Show less
Lisa Martine Jenkins

Lisa Martine Jenkins is a senior reporter at Protocol covering climate. Lisa previously wrote for Morning Consult, Chemical Watch and the Associated Press. Lisa is currently based in Brooklyn, and is originally from the Bay Area. Find her on Twitter ( @l_m_j_) or reach out via email (ljenkins@protocol.com).

Latest Stories
Bulletins